ArticleJournal of clinical medicine2023

The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms.

Dilvin Semo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.